
**Supplementary Table 1**: **Association between PD-L1 score and clinical characteristics, for each antibody**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **E1L3N antibody**  **(*n* = 32)** | | | **5H1 antibody**  **(*n* = 30)** | | |
| Positive score (*n* = 6)  *n* (%) | Negative score (*n* = 26)  *n* (%) | p-value\* | Positive score  (*n* = 3)  *n* (%) | Negative score  (*n* = 27)  *n* (%) | p-value\* |
| **Age median 51.1 years**  ≤ median  > median | 4 (66.7)  2 (33.3) | 12 (46.2)  14 (53.8) | 0.36 | 1 (33.3)  2 (66.6) | 14 (51.9)  13 (48.5) | 0.74 |
| **Gender**  Male  Female | 5 (83.3)  1 (16.7) | 23 (88.5)  3 (11.5) | 0.93 | 3 (100)  0 | 3 (11.1)  24 (88.9) | 1 |
| **Smoking status**  Never  Current/former | 0  6 (100) | 1 (3.8)  25 (96.2) | 0.21 | 0  3 (100) | 1 (3.7)  26 (96.3) | 0.40 |
| **Histology**  Adenocarcinoma  Squamous cell  Large cell | 5 (83.3)  1 (16.7)  0 | 21 (80.8)  4 (15.4)  1 (3.8) | 0.79 | 3 (100)  0  0 | 21 (77.8)  4 (14.8)  2 (7.4) | 0.69 |
| **TNM stage**  I  II  III  IV | 1 (16.7)  0  3 (50)  2 (33.3) | 2 (7.8)  4 (15.6)  11 (42.3)  11 (42.3) | 0.78 | 0  0  1 (33.3)  2 (66.6) | 2 (7.4)  4 (14.8)  11 (40.7)  10 (37.0) | 0.75 |

\*: Mann-Withney U-test; TNM: tumor node metastasis; PD-L1: programmed cell death protein 1 to PD ligand 1; HIV: human immunodeficiency virus

**Supplementary figure 1: Flow chart of tumors from HIV-positive population.**

PD-L1: programmed cell death protein 1 to PD ligand 1.



**Supplementary figure 2: Overall survival of HIV-positive patients according to PD-L1 score (positive or negative) and to antibody (A: clone E1L3N; B: clone 5H1).** Analysis were performed using a Cox survival analysis.

